Day One Biopharmaceuticals, Inc. ( DAWN )

Derivative

Common Stock

57,310

-^{footnote F1,F2}

Apr 23, 2026

Derivative

Stock Option (right to buy Common Stock)

40,000

-^{footnote F4}

Apr 23, 2026

Derivative

Stock Option (right to buy Common Stock)

40,300

-^{footnote F4}

Apr 23, 2026

Derivative

Stock Option (right to buy Common Stock)

28,700

-^{footnote F4}

Apr 23, 2026

Derivative

Stock Option (right to buy Common Stock)

37,500

-^{footnote F4}

Apr 23, 2026

Derivative

Stock Option (right to buy Common Stock)

32,335

-^{footnote F4}

Apr 23, 2026

Derivative

Stock Option (right to buy Common Stock)

22,500

-^{footnote F4}

Apr 23, 2026

Derivative

Restricted Stock Unit (RSU)

15,000

-^{footnote F4}

Footnote F1 (price): On March 6, 2026, Servier Pharmaceuticals LLC, a Delaware limited liability company ("Parent"), Servier Detroit Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"), Day One Biopharmaceuticals, Inc., a Delaware corporation (the "Company"), and… Full note on SEC EDGAR
Footnote F2 (price): Upon the closing of the Merger on April 23, 2026, each issued and outstanding share of the Company's Common Stock, par value $0.0001 per share, was either (x) purchased for $21.50 per share (the "Offer Price"), net to the seller in cash, without interest, and subject to… Full note on SEC EDGAR
Footnote F4 (price): Immediately prior to the effective time of the Merger, all outstanding unvested stock options and unvested restricted stock units became fully vested. At the effective time of the Merger, each stock option and restricted stock unit was canceled and converted into the right to… Full note on SEC EDGAR

Apr 23, 2026

Derivative

Stock Option (right to buy Common Stock)

22,500

-^{footnote F4}

Apr 23, 2026

Derivative

Restricted Stock Unit (RSU)

15,000

-^{footnote F4}

Apr 23, 2026

Derivative

Common Stock

40,485

-^{footnote F1,F2}

Apr 23, 2026

Derivative

Stock Option (right to buy Common Stock)

40,000

-^{footnote F4}

Apr 23, 2026

Derivative

Stock Option (right to buy Common Stock)

47,581

-^{footnote F4}

Apr 23, 2026

Derivative

Stock Option (right to buy Common Stock)

28,700

-^{footnote F4}

Apr 23, 2026

Derivative

Stock Option (right to buy Common Stock)

37,500

-^{footnote F4}

Apr 23, 2026

Derivative

Stock Option (right to buy Common Stock)

32,335

-^{footnote F4}

Footnote F1 (price): On March 6, 2026, Servier Pharmaceuticals LLC, a Delaware limited liability company ("Parent"), Servier Detroit Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"), Day One Biopharmaceuticals, Inc., a Delaware corporation (the "Company"), and… Full note on SEC EDGAR
Footnote F2 (price): Upon the closing of the Merger on April 23, 2026, each issued and outstanding share of the Company's Common Stock, par value $0.0001 per share, was either (x) purchased for $21.50 per share (the "Offer Price"), net to the seller in cash, without interest, and subject to… Full note on SEC EDGAR
Footnote F4 (price): Immediately prior to the effective time of the Merger, all outstanding unvested stock options and unvested restricted stock units became fully vested. At the effective time of the Merger, each stock option and restricted stock unit was canceled and converted into the right to… Full note on SEC EDGAR

Apr 23, 2026

Derivative

Common Stock

72,292

-^{footnote F1,F2}

Apr 23, 2026

Derivative

Stock Option (right to buy Common Stock)

63,000

-^{footnote F4}

Apr 23, 2026

Derivative

Stock Option (right to buy Common Stock)

1,181

-^{footnote F4}

Apr 23, 2026

Derivative

Stock Option (right to buy Common Stock)

28,700

-^{footnote F4}

Apr 23, 2026

Derivative

Stock Option (right to buy Common Stock)

37,500

-^{footnote F4}

Apr 23, 2026

Derivative

Stock Option (right to buy Common Stock)

32,335

-^{footnote F4}

Apr 23, 2026

Derivative

Stock Option (right to buy Common Stock)

22,500

-^{footnote F4}

Apr 23, 2026

Derivative

Restricted Stock Unit (RSU)

15,000

-^{footnote F4}

Footnote F1 (price): On March 6, 2026, Servier Pharmaceuticals LLC, a Delaware limited liability company ("Parent"), Servier Detroit Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"), Day One Biopharmaceuticals, Inc., a Delaware corporation (the "Company"), and… Full note on SEC EDGAR
Footnote F2 (price): Upon the closing of the Merger on April 23, 2026, each issued and outstanding share of the Company's Common Stock, par value $0.0001 per share, was either (x) purchased for $21.50 per share (the "Offer Price"), net to the seller in cash, without interest, and subject to… Full note on SEC EDGAR
Footnote F4 (price): Immediately prior to the effective time of the Merger, all outstanding unvested stock options and unvested restricted stock units became fully vested. At the effective time of the Merger, each stock option and restricted stock unit was canceled and converted into the right to… Full note on SEC EDGAR

Apr 23, 2026

Derivative

Stock Option (right to buy Common Stock)

48,072

-^{footnote F2,F3,F4}

Apr 23, 2026

Derivative

Stock Option (right to buy Common Stock)

28,700

-^{footnote F2,F3,F4}

Apr 23, 2026

Derivative

Stock Option (right to buy Common Stock)

37,500

-^{footnote F2,F3,F4}

Apr 23, 2026

Derivative

Stock Option (right to buy Common Stock)

32,335

-^{footnote F2,F3,F4}

Apr 23, 2026

Derivative

Stock Option (right to buy Common Stock)

22,500

-^{footnote F2,F3,F4}

Apr 23, 2026

Derivative

Restricted Stock Unit (RSU)

15,000

-^{footnote F2,F3,F4}

Footnote F2 (price): On March 6, 2026, Servier Pharmaceuticals LLC, a Delaware limited liability company ("Parent"), Servier Detroit Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"), Day One Biopharmaceuticals, Inc., a Delaware corporation (the "Company"), and… Full note on SEC EDGAR
Footnote F3 (price): Upon the closing of the Merger on April 23, 2026, each issued and outstanding share of the Company's Common Stock, par value $0.0001 per share, was either (x) purchased for $21.50 per share (the "Offer Price"), net to the seller in cash, without interest, and subject to… Full note on SEC EDGAR
Footnote F4 (price): Immediately prior to the effective time of the Merger, all outstanding unvested stock options and unvested restricted stock units became fully vested. At the effective time of the Merger, each stock option and restricted stock unit was canceled and converted into the right to… Full note on SEC EDGAR

Apr 23, 2026

Derivative

Stock Option (right to buy Common Stock)

66,660

-^{footnote F2,F3,F4}

Apr 23, 2026

Derivative

Stock Option (right to buy Common Stock)

32,335

-^{footnote F2,F3,F4}

Apr 23, 2026

Derivative

Stock Option (right to buy Common Stock)

22,500

-^{footnote F2,F3,F4}

Apr 23, 2026

Derivative

Restricted Stock Unit (RSU)

15,000

-^{footnote F2,F3,F4}

Footnote F2 (price): On March 6, 2026, Servier Pharmaceuticals LLC, a Delaware limited liability company ("Parent"), Servier Detroit Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"), Day One Biopharmaceuticals, Inc., a Delaware corporation (the "Company"), and… Full note on SEC EDGAR
Footnote F3 (price): Upon the closing of the Merger on April 23, 2026, each issued and outstanding share of the Company's Common Stock, par value $0.0001 per share, was either (x) purchased for $21.50 per share (the "Offer Price"), net to the seller in cash, without interest, and subject to… Full note on SEC EDGAR
Footnote F4 (price): Immediately prior to the effective time of the Merger, all outstanding unvested stock options and unvested restricted stock units became fully vested. At the effective time of the Merger, each stock option and restricted stock unit was canceled and converted into the right to… Full note on SEC EDGAR

Apr 23, 2026

Derivative

Stock Option (right to buy Common Stock)

66,660

-^{footnote F2,F3,F4}

Apr 23, 2026

Derivative

Stock Option (right to buy Common Stock)

32,335

-^{footnote F2,F3,F4}

Apr 23, 2026

Derivative

Stock Option (right to buy Common Stock)

22,500

-^{footnote F2,F3,F4}

Apr 23, 2026

Derivative

Restricted Stock Unit (RSU)

15,000

-^{footnote F2,F3,F4}

Footnote F2 (price): On March 6, 2026, Servier Pharmaceuticals LLC, a Delaware limited liability company ("Parent"), Servier Detroit Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"), Day One Biopharmaceuticals, Inc., a Delaware corporation (the "Company"), and… Full note on SEC EDGAR
Footnote F3 (price): Upon the closing of the Merger on April 23, 2026, each issued and outstanding share of the Company's Common Stock, par value $0.0001 per share, was either (x) purchased for $21.50 per share (the "Offer Price"), net to the seller in cash, without interest, and subject to… Full note on SEC EDGAR
Footnote F4 (price): Immediately prior to the effective time of the Merger, all outstanding unvested stock options and unvested restricted stock units became fully vested. At the effective time of the Merger, each stock option and restricted stock unit was canceled and converted into the right to… Full note on SEC EDGAR

Apr 23, 2026

Derivative

Stock Option (right to buy Common Stock)

33,900

-^{footnote F2,F3,F4}

Apr 23, 2026

Derivative

Stock Option (right to buy Common Stock)

37,500

-^{footnote F2,F3,F4}

Apr 23, 2026

Derivative

Stock Option (right to buy Common Stock)

32,335

-^{footnote F2,F3,F4}

Apr 23, 2026

Derivative

Stock Option (right to buy Common Stock)

22,500

-^{footnote F2,F3,F4}

Apr 23, 2026